Table 2.
Characteristics of patients
| Characteristic | Drug, trial | ||||
|---|---|---|---|---|---|
| Dabigatran RE‐LY | Rivaroxaban ROCKET AF | Apixaban ARISTOTLE | Edoxaban ENGAGE AF | Rivaroxaban J ROCKET | |
| Randomized | 18 113 | 14 264 | 18 201 | 21 105 | 1280 |
| Age (years) | 72 (mean) | 73 (median) | 70 (median) | 72 (median) | 71 (mean) |
| Male gender (%) | 64 | 60 | 65 | 62 | 81 |
| Atrial fibrillation type | |||||
| Permanent/persistent (%) | 67 | 81 | 83 | 75 | NA |
| Paroxysmal (%) | 33 | 18 | 17 | 25 | NA |
| CHADS 2 score (mean) | 2.1 | 3.5 | 2.1 | 2.8 | 3.3 |
| Prior stroke/TIA (%) | 20 | 55 | 19 | 28 | 64 |
| VKA naive (%) | 50 | 37 | 43 | 41 | 10 |
| Region * | |||||
| Europe, n (%) | 6770 (38) | 7596 (53) | 7343 (40) | 10 380 (49) | 0 (0) |
| Western Europe | 4651 (26) | 2096 (15) | 3693 (20) | 3236 (15) | — |
| Eastern Europe | 2119 (12) | 5500 (38) | 3650 (20) | 7144 (34) | — |
| Other regions, n (%) | 11 343 (62) | 6668 (47) | 10 858 (60) | 10 725 (51) | 1280 (100) |
| North America | 6533 (36) | 2681 (19) | 4474 (25) | 4681 (22) | — |
| Latin America | 956 (5) | 1878 (13) | 3468 (19) | 2661 (13) | — |
| Asia Pacific, other | 3854 (21) | 2109 (15) | 2916 (16) | 3383 (16) | 1280 (100) |
NA, not available.
*
The distribution by region corresponds to randomized patients. Calculation of numbers of patients enrolled in Western and Eastern Europe in ARISTOTLE was made based on patients enrolled by countries (see Supplementary Appendix).